Clinical ResearchA Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease: The EXECUTIVE Trial (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease)
Under an Elsevier user license
open archive
Key Words
coronary artery disease
drug-eluting stent(s)
multivessel disease
randomized clinical trial
Abbreviations and Acronyms
CAD
coronary artery disease
CI
confidence interval
DES
drug-eluting stent(s)
EES
everolimus-eluting stent(s)
MACE
major adverse cardiac event(s)
MLD
minimal lumen diameter
MV
multivessel
PCI
percutaneous coronary intervention
PES
paclitaxel-eluting stent(s)
QCA
quantitative coronary angiography
TVR
target vessel revascularization
Cited by (0)
This study was sponsored by Abbott Vascular Knoll-Ravizza S.p.A., Italy. Dr. Ribichini has received a fee from Abbott Vascular Knoll-Ravizza S.p.A. to design the study, develop the statistical analysis, and write the manuscript. Dr. Bartorelli is on the advisory board of Abbott Vascular. Drs. Lopera Quijada, Cappi, and Ribaldi are employees of Abbott Vascular Knoll-Ravizza S.p.A. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.